Effects of informant replacement in Alzheimer's disease clinical trials.

ABSTRACT:

Introduction

Alzheimer's disease (AD) trials require enrollment with an informant.

Methods

We assessed relationships between informant replacement and Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scores across four AD trials. Using generalized estimating equations, we examined associations between replacement and change in ADCS-ADL between successive visits. We used analysis of covariance to estimate the association between replacement and 18-month change from baseline, and an F-test to compare the variance of this change.

Results

Among 1336 participants, 63 (≈5%) experienced replacement. Between-visit mean change in ADCS-ADL was 2.44 points lower comparing replacement to stable informants (95% confidence interval [CI]: -3.91, -0.

SUBMITTER: Nishida MK 

PROVIDER: S-EPMC10716564 | biostudies-literature | 2023 Oct-Dec

REPOSITORIES: biostudies-literature